logo
Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic Neoplasms

Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic Neoplasms

Business Wire20-05-2025
LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)-- Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today the launch of a newly established next generation sequencing service at the Summit Health laboratory in Woodland Park, NJ to offer comprehensive DNA and RNA profiling of solid tumors and hematologic neoplasms. The internalized GTC testing menu includes tissue and bone marrow-based DNA and RNA next generation sequencing of hematologic neoplasms and solid tumors. Summit Health will now offer GTC's peripheral blood and CSF-based liquid biopsy, Liquid Trace. This revolutionary liquid biopsy assay analyzes cell free DNA and RNA (cfDNA and cfRNA) for hematologic neoplasms and solid tumors. This testing provides Summit/Village MD clinicians with a comprehensive precision diagnosis and monitoring tools to deliver state-of-the-art precision care for their patients. By running the tests locally in-house, Summit Health will reduce their send-out burden to multiple labs, standardize collection of data, shorten turn-around time and have the opportunity to participate in R&D, clinical trials and the development of IP.
As a member of the GTC Co-Op group, Summit Health will gain access to cutting-edge scientific capabilities, access to a pipeline of innovation in diagnostics, and proprietary technology and datasets for R&D.
"We are very thrilled to partner with GTC in internalizing and adopting their comprehensive portfolio of tissue and liquid biopsy tests for hematologic neoplasms and solid tumors. We believe that this testing is currently essential for the practice of precision medicine,' said Dr. Gordana Katava, DO, Chief of Pathology and Laboratory Medicine, Summit Health/Village MD.
Dr. Maher Albitar, Founder, CEO and Chief Medical Officer at GTC, stated, 'We are excited to add Summit and Village MD physicians to our Co-Op network. GTC was established on the promise of democratizing genomic science and next generation sequencing. This partnership is a step forward toward achieving our goal,' Dr. Albitar added. 'The Co-OP model is not only standardizing next generation sequencing, but also providing ecosystem for cooperation, sharing knowledge and AI-based software, and reducing cost of internalizing NGS.'
About Summit Health
Summit Health, which is a part of VillageMD, helps patients with all their comprehensive primary care and multi-specialty care needs. Whether it's getting annual checkups, raising a family, or prioritizing healthy aging, Summit Health works as a team to deliver care that helps patients make the right choices and stay a step ahead of any issues. Summit Health offers high-quality connected care services covering nearly every medical specialty including orthopedics, urology, dermatology, cardiology, gastroenterology, and more. When patients need urgent care, they can visit Summit Health's urgent care partner, CityMD, which has 180+ locations throughout N.Y. and N.J. Together, Summit Health and CityMD are one connected care team.
About GTC
Genomic Testing Cooperative [GTC], the global leader in RNA innovation, is a privately owned molecular testing company located in Lake Forest, California. Since its inception in 2018 GTC has been focused on facilitating the acceleration of access to NGS enabled precision medicine in Oncology through innovative science and differentiated business models and practices and has grown through the realization of these strategies to become a leading partner/provider in the Oncology NGS space helping healthcare organizations to tackle the biggest problems in Next Generation Sequencing for Oncology today.
Forward Looking Statements
All the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on GTC and Summit Health management's current expectations and include statements regarding the value of Molecular profiling, testing, therapy, and the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and Summit Health or GTC undertake no duty to update this information unless required by law.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Make Sure to Stay on Top of These 6 Blood Tests When Monitoring Your Health
Make Sure to Stay on Top of These 6 Blood Tests When Monitoring Your Health

CNET

time3 days ago

  • CNET

Make Sure to Stay on Top of These 6 Blood Tests When Monitoring Your Health

Having your blood drawn might not be much fun, but regular diagnostic tests of your blood can detect diseases early for treatment and give your doctor and medical providers critical information about how well your body is functioning. The proper frequency of these blood tests depends on your age and personal health status -- the most important thing is to ask your doctor which tests you need and when you need them. With all the different types of blood tests out there, it's good to go into your health care provider with a sense of what the most popular tests do and how they work. To help you out, we spoke with doctors for their expert insights about some important blood tests you may want to talk to your doctor about. 1. Complete blood count The complete blood count routine test provides a snapshot of your body's blood production and immunity. The test measures a variety of components in your blood, including red blood cells, white blood cells and platelets. Dr. Soma Mandal, a board-certified internist at Summit Health in New Providence, New Jersey, says that getting a CBC test is "recommended for individuals of all ages as part of a routine health examination or when symptoms suggest a potential health issue." Dr. Maria Knöbel, medical director of Medical Cert UK, agrees that this foundational test is appropriate for many patients. She says the test is ideal for anyone undergoing a routine health check-up. Still, she advises that you may want to get it if you're "experiencing symptoms like persistent fatigue, unexplained bruising or frequent infections." A CBC blood test can indicate lots of things, including: Allergies Anemia Certain cancers Heart disease Immune system disorders Infection Inflammation Iron deficiency Leukemia Low platelets (can affect blood clotting) Risk of clotting and bleeding Vitamin deficiency Mandal explains that each lab may have slight variations for what they consider "normal" test results. The ranges typically accepted as normal for adults are: Red blood cells: 4.5-5.9 million cells per microliter (men), 4.1-5.1 million cells per microliter (women) White blood cells: 4,500-11,000 cells per microliter Hemoglobin: 13.8-17.2 grams per deciliter (men), 12.1-15.1 grams per deciliter (women) Hematocrit: 40.7%-50.3% (men), 36.1%-44.3% (women) Platelets: 150,000-450,000 platelets per microliter 2. Lipid panel Lipids are fats and fatty substances in your blood. One type of lipid is cholesterol, which is used as a source of energy. Too much "bad" cholesterol (low-density lipoprotein or LDL) can damage your heart. You may need to get this test if you have cardiovascular disease or other risk factors. Mandal states this test is essential for anyone "at risk of cardiovascular diseases, including those with a family history of heart disease, smokers, people with hypertension or those who are overweight." Knöbel explains that a lipid panel measures total cholesterol and also breaks it down into HDL/LDL: Triglycerides LDL (bad cholesterol) HDL (good cholesterol) She says, "Elevated LDL levels are associated with an increased risk of heart disease, while high HDL levels are generally protective. Elevated triglycerides can also indicate a risk for heart disease and may be associated with other conditions like diabetes." The normal parameters for a lipid panel in adults are: Total cholesterol: Less than 200 mg/dL LDL cholesterol: Less than 100 mg/dL HDL cholesterol: 40 mg/dL or higher (men), 50 mg/dL or higher (women) Triglycerides: Less than 150 mg/dL3. Basic metabolic panel The basic metabolic panel (BMP) measures what Knöbel calls "critical aspects of your body's chemistry." This includes glucose, calcium and electrolytes such as sodium, potassium and bicarbonate. The test also looks for kidney function indicators, such as blood urea nitrogen and creatinine. "Glucose levels provide insight into blood sugar control," Knöbel explains. "Electrolyte imbalances can reveal issues related to dehydration, kidney disease or metabolic imbalances. Abnormal calcium levels can indicate issues with bone health or parathyroid function." BMP is often part of a routine exam. It also may be recommended for patients with diabetes or kidney disease or those at risk for these conditions. The results of your BMP could indicate: Dehydration Deteriorating bone health Diabetes Hypertension Kidney disease For adults, Mandal says the normal ranges for results of this test are: Bicarbonate: 23-30 mEq/L Blood urea nitrogen (BUN): 7-20 mg/dL Calcium: 8.5-10.2 mg/dL Chloride: 96-106 mEq/L Creatinine: 0.6-1.3 mg/dL Glucose: 70-99 mg/dL (fasting) Potassium: 3.5-5.0 mEq/L Sodium: 135-145 mEq/L 4. Hemoglobin A1C The Hemoglobin A1C test, also called the HbA1c, is a blood test that measures your average blood sugar level over the past 2-3 months. Mandel explains that it's primarily used to diagnose and monitor diabetes and pre-diabetes. If you're overweight, have symptoms of diabetes, have a family history of diabetes or are over the age of 45, the doctor says you may also want to get this test. A daily sugar test gives you a short-term view of your blood sugar level. On the other hand, this test is a long-term view of how well your body is managing glucose. Getting an HbA1c test could reveal a few things about your health: Diabetes Poor blood sugar control (higher risk of diabetes-related complications) Pre-diabetes Normal ranges for test results are: Normal: Less than 5.7% Pre-diabetes: 5.7% to 6.4% Diabetes: 6.5% or higher 5. Thyroid function tests If you are experiencing fatigue, weight changes, irregular heartbeat, hair loss or mood swings, you may want to get a thyroid function test. Typically prescribed only if you display symptoms such as those previously mentioned, this test measures the amount of thyroid-stimulating hormone in your blood. Your doctors can use the results to see how well your thyroid (a small, hormone-releasing gland in the front of your throat) is functioning. Mandal tells us this test is commonly included in routine health screenings, especially in women older than 60. Your blood test may indicate: High TSH levels/hypothyroidism (an underactive thyroid) Low TSH levels/hyperthyroidism (an overactive thyroid) Abnormal levels of T3 and T4 (other thyroid disorders) Doctors typically consider the following normal ranges for test results in adults: TSH levels: 0.4-4.0 mIU/L Free T4 levels: 0.8-1.8 ng/dL Free T3 levels: 2.3-4.2 pg/mL 6. 25-hydroxy vitamin D According to Mount Sinai, a hospital system in New York, some older patients can benefit from getting a 25-hydroxy test to check their vitamin D levels. People who are older than 65, have osteoporosis, get limited sun exposure and/or have celiac disease, Crohn's disease or ulcerative colitis may benefit from the test. Most people get ample vitamin D from the sun. Both skin production and gut absorption of the vitamin declines as we age. It's important to find out if you don't have enough vitamin D because it helps with everything from bone health to immunity and energy levels. The 25-hydroxy vitamin D will reveal two things: 25 hydroxy vitamin D3 (cholecalciferol) 25 hydroxy vitamin D2 (ergocalciferol) There is some disagreement among doctors about what a healthy range is for vitamin D but one generally accepted range is 20 and 40 ng/mL. Blood test FAQs Why are blood tests important? Blood tests are important because they can help doctors monitor your health and the effectiveness of treatments. They can also help doctors diagnose different medical conditions and determine the best treatment path. If my blood tests are normal, could I still have cancer? Routine blood tests may not be able to detect most types of cancer so even if your blood tests come back normal, you could still have cancer. Cancers also require additional diagnostic and laboratory testing for confirmation. If you're concerned about a certain type of cancer, discuss this with your doctor. Which blood tests need to be fasting? According to Harvard Health, fasting is often advised before tests such as glucose (blood sugar) and triglycerides, the latter of which is part of the cholesterol or lipid panel. Consult your doctor if you're confused about how long you should fast before your blood tests. The bottom line It's always important to discuss your health and any related concerns with your doctor before requesting any type of test. Based on your personal situation and health plan, your doctor may request blood work not on this list or say that you don't need some of the above tests. As a general rule, many people can benefit from CBC, lipid panel, BMP and hemoglobin A1C even without any symptoms. Also, thyroid function and vitamin D tests should be considered if you experience any symptoms. If you're older, you may also want to talk to your physician about your vitamin D absorption. If your labs are abnormal, you may need additional screening and more frequent repeat labs. If your labs are normal, these labs may only need to be repeated once a year while doing your annual exam with your primary doctor.

Collaboration Is Key To The Future Of Cancer Research And Innovation
Collaboration Is Key To The Future Of Cancer Research And Innovation

Forbes

time3 days ago

  • Forbes

Collaboration Is Key To The Future Of Cancer Research And Innovation

Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial. Advances in next generation sequencing (NGS) technologies have enabled cancer research innovations like improvements in minimal residual disease (MRD) identification and the discovery of drugs that target genetic tumor abnormalities. These approaches were backed by collaborations between developers and genomic technology suppliers who combined their scientific expertise and manufacturing capabilities to accelerate the pace of cancer research for the patients they serve. When forming these alliances, cancer researchers are faced with a growing selection of NGS providers, some of which pitch what they consider to be disruptive solutions. These alternative solutions can, at times, focus more on speed and cost—a concept suggesting that quicker insights will reduce the need for additional sequencing, equating to more tests performed and rapid breakthroughs to market. No doubt, speed and efficiency matter. But prioritizing 'fast and new' can be detrimental to driving cancer research innovation. In my opinion, a more effective approach is partnership: entering strategic relationships with genomic providers that have the quality, knowledge and capabilities to design optimized assays that generate reproducible results, making them your trusted partner from discovery through clinical development. How Researchers Are Leveraging Partnerships The key to obtaining better, more actionable insights from NGS assays is to create flexible yet optimized end-to-end workflows from library preparation to data analysis. These workflows are all customized to the experiment at hand and led by an NGS expert who has both strong in-house capabilities and a track record of collaborating with partners that help solve labs' biggest challenges. This is not just about forming one strong alliance with an innovative technology provider—it's also about benefiting from that partner's wider network of collaborators. To streamline research, developers can work hand in hand with technology providers to create or optimize customized panels, adapters, library prep and other reagents for the most robust assay to fit their needs. Among the many applications where it's vital to prioritize quality over speed in cancer research is the identification of MRD. Researchers use NGS to identify MRD by measuring circulating cell-free DNA (cfDNA) through the presence of low-frequency mutations that are known to be associated with the cancer type being studied. The MRD research and testing field is consistently growing as new genes of interest are found in blood cancers such as leukemia, lymphoma and myeloma. To support this research, developers are engaging with vendors to design new panels. Collaborations between the developers and their strategic partners also help establish high standards and metrics, so laboratories can maintain consistent data, resulting in the most reliable and confident insights possible. The most effective collaborations benefit from enhancing their capabilities by embracing outside expertise. For instance, my company, Integrated DNA Technologies (IDT), deploys continuous improvement strategies. We also have a strategic alliance with a Bio-IT company so customers can pair insights obtained from secondary analysis platforms with tertiary variant annotation and reporting software to contextualize data for both known and newly discovered variants. Recently, we also formed an innovation hub to foster innovative ideas and advancements, and foster customer collaboration. By combining expertise, manufacturing and technology capabilities, genomics providers can stay at the forefront of emerging technologies, strengthen their own capabilities to support customers, and enhance their market knowledge. Best Practices When Entering Partnerships With NGS Technology Providers Cancer researchers must collaborate with their NGS suppliers to foster a more business-minded approach to accelerating innovation. To accomplish this, developers must view their suppliers as strategic partners and work in unison to leverage their expertise, domain knowledge and supply chain management. This comprehensive approach is beneficial for researchers: It ensures a supplier's capabilities closely align with their lab's scientific objectives, resulting in increased productivity, lower inventory costs and overall savings. View them as more than a transactional arrangement so that each party can appreciate the value of partnership to advance the industry and overcome hurdles with technology sharing, regulatory roadblocks and overall cost burden. As the partnership matures, there will be an upside, such as realizing the economic and business benefits that working together brings. When evaluating expertise, experience matters. Third-party validation, proof-of-concept, comparative testing and a diverse customer base are a few ways to assess an NGS supplier's track record. These factors help distinguish a partner that can provide quality, expertise and consistency over a vendor that displays disruptive new technology. While not all partnerships will be a good fit, in order for them to succeed, it must be a win-win and provide a synergistic benefit that fills an industry, market or technology gap, solves a customer problem, or accelerates therapeutic development. Conclusion Strategic partnerships between developers and suppliers will continue to drive important innovations in NGS for cancer research. But to truly drive maximum benefit from these partnerships, developers who want to maximize insights should prioritize expertise and quality of data over disruptive new technology focused solely on speed and cost. For cancer patients awaiting new therapies, the stakes are too high. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?

Walgreens Outlook Improves As Buyout Faces Shareholder Vote Next Month
Walgreens Outlook Improves As Buyout Faces Shareholder Vote Next Month

Forbes

time7 days ago

  • Forbes

Walgreens Outlook Improves As Buyout Faces Shareholder Vote Next Month

News that Walgreens Boots Alliance quarterly loss was better than expected and pharmacy sales were ... More rising bodes well for a financial turnaround under new ownership, analysts said after the company's June 26, 2025 earnings report. In this photo is a sign outside a Walgreens store in San Pablo, California, US, on Tuesday, Oct. 15, 2024. Photographer: David Paul Morris/Bloomberg News that Walgreens Boots Alliance quarterly loss was better than expected and pharmacy sales are rising bodes well for a financial turnaround under new ownership. Under future owner Sycamore Partners, analysts expect cost-cutting to escalate once the private equity firm's $10 billion purchase of Walgreens is complete before the end of this calendar year. One of the first major hurdles is a vote of shareholders at a special meeting on July 11. But there's been no serious opposition that has emerged to the purchase by Sycamore, which is paying $11.45 per share — 29% above the December stock price. Sycamore also agreed to 'one non-transferable right" to receive up to $3 in cash per Walgreens share 'from the future monetization of WBA's debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses,' the companies said of Walgreens' primary care businesses. Walgreens reported a net loss of $175 million, or 20 cents a share, in the company's fiscal third quarter ended May 31 compared to net income of $344 million, or 40 cents a share, in the year-ago period. Total sales rose 7% to $39 billion in its third quarter. Walgreens chief executive officer Tim Wentworth highlighted what he called 'continued improvement' in the company's U.S. Healthcare segment, that includes Village Medical, Summit and CityMD. The U.S. healthcare segment, which reported $2.1 billion in third quarter sales, reported an operating loss of $64 million, which was much improved over the operating loss of $220 million in the year-ago quarter, 'reflecting lower acquisition-related amortization and higher contributions from VillageMD risk-based business,' Walgreens said. Meanwhile, analysts were impressed with Walgreens ability to produce 'positive free cash flow in the quarter, a key positive given recent negative free cash flow trends,' Ann Hynes and colleagues at Mizuho Securities USA wrote in a report Thursday. 'WBA continues to expect Sycamore Partner's acquisition of the company to close in either the third of fourth quarter of calendar year 2025.' The Sycamore deal comes after Walgreens, which had a market value of more than $100 billion a decade ago, undertook the failed VillageMD in-store clinic rollout that led it to close hundreds of stores to reduce debt and stem financial losses. Wentworth said Walgreens is benefiting from 'cost savings initiatives' that include closing underperforming stores. Walgreens is on pace to meet its goal of closing 1,200 stores by its fiscal 2027. The company, which operates about 8,000 U.S. stores, has closed a little more than 400 stores in the first nine months of its fiscal year ended May 31 and said it would close 500 in this fiscal year. Walgreens third quarter results were much improved over its second quarter when the company in March reported a $2.8 billion loss thanks to a large impairment charge related to its struggling doctor-staffed clinic investment in VillageMD. Analysts who follow Walgreens see the move to private ownership as another plus because the company and a stock price attached to public ownership will no longer be subject to the whims of Wall Street. 'By making the move to go private, Walgreens will have the time for reinvention, something not possible as a public company chasing quarterly numbers," said Dave Mayer, Senior Partner at the brand consultancy Lippincott.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store